Lyell is an immuno-oncology company dedicated to reprogramming T cells to achieve curative therapies for solid tumors. The company takes a deliberate approach to solving what it believes to be the major barriers to successful adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is combining its proprietary ex vivo genetic and epigenetic reprogramming technologies that address these barriers with T cell receptors (TCRs), tumor-infiltrating lymphocytes (TILs) and chimeric antigen receptors (CARs). 

Biotechnology

Therapeutics

Lyell Immunopharma

The Bothell office focuses on quality assurance, manufacturing, and clinical trial management in the biotech sector.

Bothell

Lyell Immunopharma's headquarters in South San Francisco, CA, United States

People (73)

Jobs (0)

Other offices